Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | T-2143 |
Synonyms | |
Therapy Description |
T-2143 is an HSP90-PI3K drug conjugate, which selectively targets PI3K, potentially resulting in decreased tumor cell proliferation and reduced tumor growth (PMID: 32499300). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
T-2143 | T2143|T 2143 | T-2143 is an HSP90-PI3K drug conjugate, which selectively targets PI3K, potentially resulting in decreased tumor cell proliferation and reduced tumor growth (PMID: 32499300). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PIK3CA E545K | lung non-small cell carcinoma | sensitive | T-2143 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, T-2143 treatment reduced proliferation of non-small cell lung cancer cells harboring PIK3CA E545K in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 32499300). | 32499300 |
PIK3CA H1047R | colon cancer | sensitive | T-2143 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, T-2143 treatment inhibited Akt phosphorylation and proliferation of colon cancer cells harboring PIK3CA H1047R in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 32499300). | 32499300 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|